Aurobindo Pharma receives USFDA approval for Vecuronium Bromide Injection

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Vecuronium Bromide Injection, 10mg and 20mg. Aurobindo's Vecuronium Bromide Injection is a generic equivalent of Organon's Norcuron Injection. The product will be launched in Q4FY19.

Vecuronium Bromide Injection is used as part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is also used to facilitate endotracheal intubation. The approved product has an estimated market size of US$ 11 million for the twelve months ending September 2018 according to IQVIA.

Powered by Capital Market - Live News